MongoDB closes a remarkable two-week earnings cycle with the Street firmly in its corner — even as the stock pulls back 4.2% on September 1 to $434.21, the analyst response to its second August print has been the most coordinated target-raising wave of the year.
Ten firms updated their views on September 2 alone, and the direction was overwhelmingly bullish. Goldman Sachs lifted its target from $453 to $520, maintaining Buy. Citigroup moved to $565 from $545, also keeping Buy. Piper Sandler, Canaccord, Bernstein, and Mizuho all raised targets — each maintaining positive ratings. Only UBS and BMO bucked the trend, trimming targets to $410 and $450 respectively while holding Neutral and Outperform. The consensus mean price target now sits at $454, which at the September 1 close of $434 represents roughly 5% implied upside from the Street's collective pencil — a tighter gap than the one that existed before either August print, but still positive. The bull case centers on Atlas revenue acceleration, AI-driven monetisation, and a 28% revenue growth trajectory. Bears point to PostgreSQL competition and dependence on the agentic app development cycle as structural risks worth monitoring.
Previous notes flagged that short interest climbed sharply after each of the two August earnings events. That pattern has continued. Shorts added another 34% on the week to reach 3.7% of the free float — the highest level since late July, when the position was closer to 4.5%. The absolute level remains modest, and the lending market provides no friction for bears. Availability stands at roughly 6,300% — meaning there are more than sixty times as many shares available to borrow as are currently borrowed — and cost to borrow has eased to just 0.40%, down from 0.54% a month ago. Bears can position cheaply and easily. The ORTEX short score has drifted higher through the week, reaching 34.1 — up from 30.6 ten days ago — but the level is well within ordinary territory for a mid-cap growth stock.
Options positioning has nudged slightly more defensive but not materially so. The put/call ratio moved to 0.60 on September 1, about 1.35 standard deviations above its 20-day average of 0.57. That is elevated relative to recent weeks but a long way from the 52-week high of 1.34. Calls still dominate the flow — the ratio is far from fearful. Taken together with the loose lending market, the positioning picture reads as modestly cautious rather than charged.
The valuation picture reflects the stock's sharp month-long recovery. The P/E multiple has expanded roughly 35% in 30 days to 63.6x, and price-to-book has added 2.5 turns to reach 9.5x. EV/EBITDA at 47x is running above where it sat a month ago. The forward EPS growth factor score ranks in the 94th percentile of the universe — the Street has been marking up estimates aggressively — but momentum and sector scores sit near the median at 50. The stock needs that earnings growth to keep arriving to justify multiple expansion from here.
From an ownership standpoint, BlackRock reported adding 617,000 shares to reach 7.9% of the company as of late July. FMR added 1.46 million shares in the same period, building toward 4.4%. Both moves pre-date the earnings-driven rally. Insider data in the snapshot is stale — the most recent filings are from January 2026, all pre-planned 10b5-1 sales by Director Dwight Merriman — and carries no current signal.
The next scheduled earnings event is September 29. With the stock sitting 4% below the consensus target after a two-print earnings season that generated a surge of upward revisions, the focus between now and then shifts to whether peer pressure — TWLO and NET fell 3% and 6.4% respectively on September 1, while OKTA gained 27% on the week — sustains or disrupts the recovery narrative that has carried MDB up 29% over the past month.
See the live data behind this article on ORTEX.
Open MDB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
